Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-05-11

AUTHORS

Mitsuhiro Hayashi, Yasuhiro Okumura, Tomofumi Osako, Yasuo Toyozumi, Nobuyuki Arima, Hirotaka Iwase, Reiki Nishimura

ABSTRACT

BackgroundTrastuzumab demonstrates significant clinical benefits in HER2-positive metastatic breast cancer (MBC), and recent clinical trials suggest that trastuzumab should be continued in combination with other chemotherapy beyond progression. There is an urgent need to assess if patients could substantially benefit from continuing trastuzumab-based therapy.MethodsWe reviewed 91 patients with HER2-positive MBC treated with trastuzumab and investigated correlations between survival and clinical response to first trastuzumab-based therapy and biological markers, time to first tumor progression (1st TTP), response rate (RR), estrogen receptor (ER), Ki-67, and p53 overexpression.ResultsWith a median follow-up of 33 months, 76 patients had received two or more lines of consecutive trastuzumab-based therapy. Median 1st TTP was 8.6 months; patients who received trastuzumab with chemotherapy had a longer 1st TTP and better RR than those without chemotherapy. In terms of survival after first progression, patients with a longer 1st TTP (≥8.6 months) had significantly better survival compared with those who had a shorter 1st TTP (24.3 months vs. 15.4 months, P = 0.024), and multivariate analysis revealed that 1st TTP was a significant prognostic factor (HR 0.44, 95% CI 0.23–0.82, P = 0.01). There were no correlations between survival and ER or Ki-67; however, there was a correlation with p53 overexpression (HR 1.92, 95% CI 1.01–3.64, P = 0.045).Conclusions1st TTP is a significant prognostic factor for patients who receive subsequent trastuzumab-based therapy. This factor should be considered when determining the efficacy of continuing trastuzumab or switching to another anti-HER2 therapy beyond progression. More... »

PAGES

694-700

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1

DOI

http://dx.doi.org/10.1007/s10147-011-0251-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1048218924

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21556795


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "ErbB Receptors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ki-67 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Suppressor Protein p53", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan", 
            "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hayashi", 
        "givenName": "Mitsuhiro", 
        "id": "sg:person.01312032020.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312032020.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okumura", 
        "givenName": "Yasuhiro", 
        "id": "sg:person.01166616331.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166616331.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osako", 
        "givenName": "Tomofumi", 
        "id": "sg:person.01175256736.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175256736.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toyozumi", 
        "givenName": "Yasuo", 
        "id": "sg:person.01016230102.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016230102.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arima", 
        "givenName": "Nobuyuki", 
        "id": "sg:person.016542450374.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.274841.c", 
          "name": [
            "Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwase", 
        "givenName": "Hirotaka", 
        "id": "sg:person.01117473535.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415532.4", 
          "name": [
            "Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimura", 
        "givenName": "Reiki", 
        "id": "sg:person.013173055502.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.onc.1202132", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031382266", 
          "https://doi.org/10.1038/sj.onc.1202132"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10147-006-0601-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001769831", 
          "https://doi.org/10.1007/s10147-006-0601-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr1536", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016960147", 
          "https://doi.org/10.1186/bcr1536"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-05-11", 
    "datePublishedReg": "2011-05-11", 
    "description": "BackgroundTrastuzumab demonstrates significant clinical benefits in HER2-positive metastatic breast cancer (MBC), and recent clinical trials suggest that trastuzumab should be continued in combination with other chemotherapy beyond progression. There is an urgent need to assess if patients could substantially benefit from continuing trastuzumab-based therapy.MethodsWe reviewed 91 patients with HER2-positive MBC treated with trastuzumab and investigated correlations between survival and clinical response to first trastuzumab-based therapy and biological markers, time to first tumor progression (1st TTP), response rate (RR), estrogen receptor (ER), Ki-67, and p53 overexpression.ResultsWith a median follow-up of 33\u00a0months, 76 patients had received two or more lines of consecutive trastuzumab-based therapy. Median 1st TTP was 8.6\u00a0months; patients who received trastuzumab with chemotherapy had a longer 1st TTP and better RR than those without chemotherapy. In terms of survival after first progression, patients with a longer 1st TTP (\u22658.6\u00a0months) had significantly better survival compared with those who had a shorter 1st TTP (24.3\u00a0months vs. 15.4\u00a0months, P\u00a0=\u00a00.024), and multivariate analysis revealed that 1st TTP was a significant prognostic factor (HR 0.44, 95% CI 0.23\u20130.82, P\u00a0=\u00a00.01). There were no correlations between survival and ER or Ki-67; however, there was a correlation with p53 overexpression (HR 1.92, 95% CI 1.01\u20133.64, P\u00a0=\u00a00.045).Conclusions1st TTP is a significant prognostic factor for patients who receive subsequent trastuzumab-based therapy. This factor should be considered when determining the efficacy of continuing trastuzumab or switching to another anti-HER2 therapy beyond progression.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10147-011-0251-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312225", 
        "issn": [
          "1341-9625", 
          "1437-7772"
        ], 
        "name": "International Journal of Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "trastuzumab-based therapy", 
      "metastatic breast cancer", 
      "HER2-positive metastatic breast cancer", 
      "first tumor progression", 
      "significant prognostic factors", 
      "estrogen receptor", 
      "response rate", 
      "prognostic factors", 
      "p53 overexpression", 
      "breast cancer", 
      "Ki-67", 
      "tumor progression", 
      "human epidermal growth factor receptor", 
      "anti-HER2 therapy", 
      "recent clinical trials", 
      "predictors of efficacy", 
      "significant clinical benefit", 
      "better response rate", 
      "terms of survival", 
      "epidermal growth factor receptor", 
      "growth factor receptor", 
      "clinical response", 
      "first progression", 
      "clinical benefit", 
      "clinical trials", 
      "better survival", 
      "patients", 
      "trastuzumab", 
      "multivariate analysis", 
      "therapy", 
      "biological markers", 
      "chemotherapy", 
      "progression", 
      "more lines", 
      "factor receptor", 
      "TTP", 
      "survival", 
      "cancer", 
      "months", 
      "receptors", 
      "efficacy", 
      "overexpression", 
      "urgent need", 
      "BackgroundTrastuzumab", 
      "MethodsWe", 
      "factors", 
      "trials", 
      "ResultsWith", 
      "treatment", 
      "correlation", 
      "predictors", 
      "markers", 
      "response", 
      "benefits", 
      "time", 
      "rate", 
      "need", 
      "combination", 
      "lines", 
      "analysis", 
      "terms"
    ], 
    "name": "Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer", 
    "pagination": "694-700", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1048218924"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10147-011-0251-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21556795"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10147-011-0251-1", 
      "https://app.dimensions.ai/details/publication/pub.1048218924"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_542.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10147-011-0251-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-011-0251-1'


 

This table displays all metadata directly associated to this object as RDF triples.

259 TRIPLES      22 PREDICATES      109 URIs      98 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10147-011-0251-1 schema:about N044cc7c7533d4d16bd145a73902770b3
2 N0dd4a465c143489482af948b1b1f492b
3 N1632e308f8884335980ca891f41d3e13
4 N17c76c50a779461a9a4e44c77548c5ba
5 N57ac1cfb209f4f9d94050a45bd09dc2e
6 N6b51eeb9231c4f08bc1a053af2a362a6
7 N753d507b10d3412eae18ad2f737a2167
8 N7e0d78ddfb4147e7beb15698f1da68b6
9 N819dd07cee3044e5b9197531e96500af
10 N8f43859f66f5443f8a7cf3713ad71dbf
11 Na87d96fa44784ab3b135c04435ab1de7
12 Nba5d8cd3f1a74befa4d955655edeaa85
13 Nc32d6a3a2b4d4568b0b1e1b11fe9c186
14 Nc58af7cd968943ae8a8c628c71324d54
15 Nc6ccaab832a74b589623f7a23d570a40
16 Ncdc26a2586994ccea3a649dac78928e1
17 Ne5bf28f05fa74d3b82d19367f2b6d0b8
18 Nf8be31677162423a86385e8afe754f0b
19 Nf99faa94ae7a4b47bbe2cf4a5e6e96ed
20 anzsrc-for:11
21 anzsrc-for:1112
22 schema:author N7fda9a3a825741a3b2612a5c239da05f
23 schema:citation sg:pub.10.1007/s10147-006-0601-6
24 sg:pub.10.1038/sj.onc.1202132
25 sg:pub.10.1186/bcr1536
26 schema:datePublished 2011-05-11
27 schema:datePublishedReg 2011-05-11
28 schema:description BackgroundTrastuzumab demonstrates significant clinical benefits in HER2-positive metastatic breast cancer (MBC), and recent clinical trials suggest that trastuzumab should be continued in combination with other chemotherapy beyond progression. There is an urgent need to assess if patients could substantially benefit from continuing trastuzumab-based therapy.MethodsWe reviewed 91 patients with HER2-positive MBC treated with trastuzumab and investigated correlations between survival and clinical response to first trastuzumab-based therapy and biological markers, time to first tumor progression (1st TTP), response rate (RR), estrogen receptor (ER), Ki-67, and p53 overexpression.ResultsWith a median follow-up of 33 months, 76 patients had received two or more lines of consecutive trastuzumab-based therapy. Median 1st TTP was 8.6 months; patients who received trastuzumab with chemotherapy had a longer 1st TTP and better RR than those without chemotherapy. In terms of survival after first progression, patients with a longer 1st TTP (≥8.6 months) had significantly better survival compared with those who had a shorter 1st TTP (24.3 months vs. 15.4 months, P = 0.024), and multivariate analysis revealed that 1st TTP was a significant prognostic factor (HR 0.44, 95% CI 0.23–0.82, P = 0.01). There were no correlations between survival and ER or Ki-67; however, there was a correlation with p53 overexpression (HR 1.92, 95% CI 1.01–3.64, P = 0.045).Conclusions1st TTP is a significant prognostic factor for patients who receive subsequent trastuzumab-based therapy. This factor should be considered when determining the efficacy of continuing trastuzumab or switching to another anti-HER2 therapy beyond progression.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf N26ff2abb9f374350b0a7a14384f1e11b
33 N722a17bf31af4516b2f0eecdb8f2fe4e
34 sg:journal.1312225
35 schema:keywords BackgroundTrastuzumab
36 HER2-positive metastatic breast cancer
37 Ki-67
38 MethodsWe
39 ResultsWith
40 TTP
41 analysis
42 anti-HER2 therapy
43 benefits
44 better response rate
45 better survival
46 biological markers
47 breast cancer
48 cancer
49 chemotherapy
50 clinical benefit
51 clinical response
52 clinical trials
53 combination
54 correlation
55 efficacy
56 epidermal growth factor receptor
57 estrogen receptor
58 factor receptor
59 factors
60 first progression
61 first tumor progression
62 growth factor receptor
63 human epidermal growth factor receptor
64 lines
65 markers
66 metastatic breast cancer
67 months
68 more lines
69 multivariate analysis
70 need
71 overexpression
72 p53 overexpression
73 patients
74 predictors
75 predictors of efficacy
76 prognostic factors
77 progression
78 rate
79 recent clinical trials
80 receptors
81 response
82 response rate
83 significant clinical benefit
84 significant prognostic factors
85 survival
86 terms
87 terms of survival
88 therapy
89 time
90 trastuzumab
91 trastuzumab-based therapy
92 treatment
93 trials
94 tumor progression
95 urgent need
96 schema:name Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer
97 schema:pagination 694-700
98 schema:productId N8401a1861ba34ab0a81ec9f597b99f40
99 N9260008121544359bf0a8324d56ca513
100 Na1db046967f3438e8d04775253631151
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048218924
102 https://doi.org/10.1007/s10147-011-0251-1
103 schema:sdDatePublished 2022-06-01T22:11
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N465bd2308d8f4adf8540a2e99802e06b
106 schema:url https://doi.org/10.1007/s10147-011-0251-1
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N044cc7c7533d4d16bd145a73902770b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Tumor Suppressor Protein p53
112 rdf:type schema:DefinedTerm
113 N0dd4a465c143489482af948b1b1f492b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Receptors, Estrogen
115 rdf:type schema:DefinedTerm
116 N159844ca5cd842f09c73bfbce494c7ca rdf:first sg:person.013173055502.44
117 rdf:rest rdf:nil
118 N1632e308f8884335980ca891f41d3e13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Antibodies, Monoclonal, Humanized
120 rdf:type schema:DefinedTerm
121 N16dc8c264384417d99ff7c6a15e0194e rdf:first sg:person.01166616331.89
122 rdf:rest N9bc1609572da4382af48d751db47a347
123 N17c76c50a779461a9a4e44c77548c5ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Breast Neoplasms
125 rdf:type schema:DefinedTerm
126 N19e18ff71c464cbd8eab26ecc6b059ee rdf:first sg:person.01117473535.84
127 rdf:rest N159844ca5cd842f09c73bfbce494c7ca
128 N26ff2abb9f374350b0a7a14384f1e11b schema:issueNumber 6
129 rdf:type schema:PublicationIssue
130 N27c769fb7b454ba2ab474268d99a37c2 rdf:first sg:person.016542450374.76
131 rdf:rest N19e18ff71c464cbd8eab26ecc6b059ee
132 N465bd2308d8f4adf8540a2e99802e06b schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 N57ac1cfb209f4f9d94050a45bd09dc2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Neoplasm Metastasis
136 rdf:type schema:DefinedTerm
137 N6b51eeb9231c4f08bc1a053af2a362a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Trastuzumab
139 rdf:type schema:DefinedTerm
140 N722a17bf31af4516b2f0eecdb8f2fe4e schema:volumeNumber 16
141 rdf:type schema:PublicationVolume
142 N753d507b10d3412eae18ad2f737a2167 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Middle Aged
144 rdf:type schema:DefinedTerm
145 N7a550a92eb3c4d9697f21ba3cbac4162 rdf:first sg:person.01016230102.90
146 rdf:rest N27c769fb7b454ba2ab474268d99a37c2
147 N7e0d78ddfb4147e7beb15698f1da68b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Female
149 rdf:type schema:DefinedTerm
150 N7fda9a3a825741a3b2612a5c239da05f rdf:first sg:person.01312032020.64
151 rdf:rest N16dc8c264384417d99ff7c6a15e0194e
152 N819dd07cee3044e5b9197531e96500af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Disease Progression
154 rdf:type schema:DefinedTerm
155 N8401a1861ba34ab0a81ec9f597b99f40 schema:name pubmed_id
156 schema:value 21556795
157 rdf:type schema:PropertyValue
158 N8f43859f66f5443f8a7cf3713ad71dbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Humans
160 rdf:type schema:DefinedTerm
161 N9260008121544359bf0a8324d56ca513 schema:name dimensions_id
162 schema:value pub.1048218924
163 rdf:type schema:PropertyValue
164 N9bc1609572da4382af48d751db47a347 rdf:first sg:person.01175256736.52
165 rdf:rest N7a550a92eb3c4d9697f21ba3cbac4162
166 Na1db046967f3438e8d04775253631151 schema:name doi
167 schema:value 10.1007/s10147-011-0251-1
168 rdf:type schema:PropertyValue
169 Na87d96fa44784ab3b135c04435ab1de7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Ki-67 Antigen
171 rdf:type schema:DefinedTerm
172 Nba5d8cd3f1a74befa4d955655edeaa85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Time Factors
174 rdf:type schema:DefinedTerm
175 Nc32d6a3a2b4d4568b0b1e1b11fe9c186 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name ErbB Receptors
177 rdf:type schema:DefinedTerm
178 Nc58af7cd968943ae8a8c628c71324d54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Adult
180 rdf:type schema:DefinedTerm
181 Nc6ccaab832a74b589623f7a23d570a40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Survival Analysis
183 rdf:type schema:DefinedTerm
184 Ncdc26a2586994ccea3a649dac78928e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Treatment Outcome
186 rdf:type schema:DefinedTerm
187 Ne5bf28f05fa74d3b82d19367f2b6d0b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Aged
189 rdf:type schema:DefinedTerm
190 Nf8be31677162423a86385e8afe754f0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Prognosis
192 rdf:type schema:DefinedTerm
193 Nf99faa94ae7a4b47bbe2cf4a5e6e96ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Follow-Up Studies
195 rdf:type schema:DefinedTerm
196 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
197 schema:name Medical and Health Sciences
198 rdf:type schema:DefinedTerm
199 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
200 schema:name Oncology and Carcinogenesis
201 rdf:type schema:DefinedTerm
202 sg:journal.1312225 schema:issn 1341-9625
203 1437-7772
204 schema:name International Journal of Clinical Oncology
205 schema:publisher Springer Nature
206 rdf:type schema:Periodical
207 sg:person.01016230102.90 schema:affiliation grid-institutes:grid.415532.4
208 schema:familyName Toyozumi
209 schema:givenName Yasuo
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016230102.90
211 rdf:type schema:Person
212 sg:person.01117473535.84 schema:affiliation grid-institutes:grid.274841.c
213 schema:familyName Iwase
214 schema:givenName Hirotaka
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117473535.84
216 rdf:type schema:Person
217 sg:person.01166616331.89 schema:affiliation grid-institutes:grid.415532.4
218 schema:familyName Okumura
219 schema:givenName Yasuhiro
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166616331.89
221 rdf:type schema:Person
222 sg:person.01175256736.52 schema:affiliation grid-institutes:grid.415532.4
223 schema:familyName Osako
224 schema:givenName Tomofumi
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01175256736.52
226 rdf:type schema:Person
227 sg:person.01312032020.64 schema:affiliation grid-institutes:grid.415532.4
228 schema:familyName Hayashi
229 schema:givenName Mitsuhiro
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312032020.64
231 rdf:type schema:Person
232 sg:person.013173055502.44 schema:affiliation grid-institutes:grid.415532.4
233 schema:familyName Nishimura
234 schema:givenName Reiki
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013173055502.44
236 rdf:type schema:Person
237 sg:person.016542450374.76 schema:affiliation grid-institutes:grid.415532.4
238 schema:familyName Arima
239 schema:givenName Nobuyuki
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016542450374.76
241 rdf:type schema:Person
242 sg:pub.10.1007/s10147-006-0601-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001769831
243 https://doi.org/10.1007/s10147-006-0601-6
244 rdf:type schema:CreativeWork
245 sg:pub.10.1038/sj.onc.1202132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031382266
246 https://doi.org/10.1038/sj.onc.1202132
247 rdf:type schema:CreativeWork
248 sg:pub.10.1186/bcr1536 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016960147
249 https://doi.org/10.1186/bcr1536
250 rdf:type schema:CreativeWork
251 grid-institutes:grid.274841.c schema:alternateName Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan
252 schema:name Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan
253 rdf:type schema:Organization
254 grid-institutes:grid.415532.4 schema:alternateName Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan
255 Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan
256 schema:name Department of Breast and Endocrine Surgery, Faculty of Life Sciences, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, 860-8556, Kumamoto, Kumamoto, Japan
257 Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto, Kumamoto, Japan
258 Department of Clinical Pathology, Kumamoto City Hospital, 1-1-60 Kotoh, 862-8505, Kumamoto-city, Kumamoto, Japan
259 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...